Extending the case for oestradiol in androgen-sensitive prostate cancer - Authors' reply

Comment

Ruth Langley et al. Lancet Oncol. 2013 Jun.

. 2013 Jun;14(7):e253.

doi: 10.1016/S1470-2045(13)70203-1.

No abstract available

Comment on

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).
Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD. Langley RE, et al. Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4. Lancet Oncol. 2013. PMID: 23465742 Free PMC article. Clinical Trial.
Extending the case for oestradiol in androgen-sensitive prostate cancer.
Wassersug RJ. Wassersug RJ. Lancet Oncol. 2013 Jun;14(7):e252-3. doi: 10.1016/S1470-2045(13)70120-7. Lancet Oncol. 2013. PMID: 23725706 No abstract available.